Unlocking the Therapeutic Applicability of LNP-mRNA: Chemistry, Formulation, and Clinical Strategies

Overview

Journal Research (Wash D C)

Specialty Biology

Date 2024 Jun 19

PMID 38894715

Authors

Xiaonan Huang

Yishan Ma

Guanghui Ma

Yufei Xia

Affiliations

Soon will be listed here.

Abstract

Messenger RNA (mRNA) has emerged as an innovative therapeutic modality, offering promising avenues for the prevention and treatment of a variety of diseases. The tremendous success of mRNA vaccines in effectively combatting coronavirus disease 2019 (COVID-19) evidences the unlimited medical and therapeutic potential of mRNA technology. Overcoming challenges related to mRNA stability, immunogenicity, and precision targeting has been made possible by recent advancements in lipid nanoparticles (LNPs). This review summarizes state-of-the-art LNP-mRNA-based therapeutics, including their structure, material compositions, design guidelines, and screening principles. Additionally, we highlight current preclinical and clinical trends in LNP-mRNA therapeutics in a broad range of treatments in ophthalmological conditions, cancer immunotherapy, gene editing, and rare-disease medicine. Particular attention is given to the translation and evolution of LNP-mRNA vaccines into a broader spectrum of therapeutics. We explore concerns in the aspects of inadequate extrahepatic targeting efficacy, elevated doses, safety concerns, and challenges of large-scale production procedures. This discussion may offer insights and perspectives on near- and long-term clinical development prospects for LNP-mRNA therapeutics.

Citing Articles

Revolutionizing Nanovaccines: A New Era of Immunization.

Saleh M, El-Moghazy A, Elgohary A, Saber W, Helmy Y Vaccines (Basel). 2025; 13(2).

PMID: 40006673 PMC: 11860605. DOI: 10.3390/vaccines13020126.

Novel lncRNA LncMSTRG.11341.25 Promotes Osteogenic Differentiation of Human Bone Marrow Stem Cells via the miR-939-5p/PAX8 Axis.

Ni F, Li J, Yin Q, Chen Y, Shao Z, Wang H Research (Wash D C). 2025; 8:0601.

PMID: 39916798 PMC: 11798881. DOI: 10.34133/research.0601.

Capturing the dynamic integrity of carbocyanine fluorophore-based lipid nanoparticles using the FRET technique.

Long S, Turner D, Hamill K, Natrajan L, McDonald T J Mater Chem B. 2025; 13(7):2295-2305.

PMID: 39886899 PMC: 11783621. DOI: 10.1039/d4tb02653e.

Emerging Roles of ncRNAs in Type 2 Diabetes Mellitus: From Mechanisms to Drug Discovery.

Yang Y, Cheng H Biomolecules. 2024; 14(11).

PMID: 39595541 PMC: 11592034. DOI: 10.3390/biom14111364.

References

Feldman R, Fuhr R, Smolenov I, Ribeiro A, Panther L, Watson M . mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019; 37(25):3326-3334. DOI: 10.1016/j.vaccine.2019.04.074. View

Li S, Hu Y, Li A, Lin J, Hsieh K, Schneiderman Z . Payload distribution and capacity of mRNA lipid nanoparticles. Nat Commun. 2022; 13(1):5561. PMC: 9508184. DOI: 10.1038/s41467-022-33157-4. View

Billingsley M, Singh N, Ravikumar P, Zhang R, June C, Mitchell M . Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 2020; 20(3):1578-1589. PMC: 7313236. DOI: 10.1021/acs.nanolett.9b04246. View

Sahin U, Tureci O . Personalized vaccines for cancer immunotherapy. Science. 2018; 359(6382):1355-1360. DOI: 10.1126/science.aar7112. View

Fenton O, Kauffman K, McClellan R, Kaczmarek J, Zeng M, Andresen J . Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs. Angew Chem Int Ed Engl. 2018; 57(41):13582-13586. PMC: 7548314. DOI: 10.1002/anie.201809056. View

Li B, Luo X, Deng B, Wang J, McComb D, Shi Y . An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo. Nano Lett. 2015; 15(12):8099-107. PMC: 4869688. DOI: 10.1021/acs.nanolett.5b03528. View

Da Silva Sanchez A, Dobrowolski C, Cristian A, Echeverri E, Zhao K, Hatit M . Universal Barcoding Predicts ApoE-Independent Lipid Nanoparticle Delivery. Nano Lett. 2022; 22(12):4822-4830. DOI: 10.1021/acs.nanolett.2c01133. View

Mui B, Tam Y, Jayaraman M, Ansell S, Du X, Tam Y . Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles. Mol Ther Nucleic Acids. 2013; 2:e139. PMC: 3894582. DOI: 10.1038/mtna.2013.66. View

Ni H, Hatit M, Zhao K, Loughrey D, Lokugamage M, Peck H . Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo. Nat Commun. 2022; 13(1):4766. PMC: 9376583. DOI: 10.1038/s41467-022-32281-5. View

10.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

11.

Zhang X, Zhao W, Nguyen G, Zhang C, Zeng C, Yan J . Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing. Sci Adv. 2020; 6(34). PMC: 7442477. DOI: 10.1126/sciadv.abc2315. View

12.

Kingwell K . First CRISPR therapy seeks landmark approval. Nat Rev Drug Discov. 2023; 22(5):339-341. DOI: 10.1038/d41573-023-00050-8. View

13.

Huang Z, Tipparaju S, Kirpotin D, Pien C, Kornaga T, Noble C . Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs. J Control Release. 2019; 310:47-57. DOI: 10.1016/j.jconrel.2019.08.006. View

14.

Hajj K, Ball R, Deluty S, Singh S, Strelkova D, Knapp C . Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH. Small. 2019; 15(6):e1805097. DOI: 10.1002/smll.201805097. View

15.

Li Y, Su Z, Zhao W, Zhang X, Momin N, Zhang C . Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nat Cancer. 2021; 1(9):882-893. PMC: 8386348. DOI: 10.1038/s43018-020-0095-6. View

16.

Goswami R, Chatzikleanthous D, Lou G, Giusti F, Bonci A, Taccone M . Mannosylation of LNP Results in Improved Potency for Self-Amplifying RNA (SAM) Vaccines. ACS Infect Dis. 2019; 5(9):1546-1558. DOI: 10.1021/acsinfecdis.9b00084. View

17.

Herrera M, Kim J, Eygeris Y, Jozic A, Sahay G . Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery. Biomater Sci. 2021; 9(12):4289-4300. PMC: 8769212. DOI: 10.1039/d0bm01947j. View

18.

Choi J, Rustique E, Henry M, Guidetti M, Josserand V, Sancey L . Targeting tumors with cyclic RGD-conjugated lipid nanoparticles loaded with an IR780 NIR dye: In vitro and in vivo evaluation. Int J Pharm. 2017; 532(2):677-685. DOI: 10.1016/j.ijpharm.2017.03.007. View

19.

Dolgin E . The tangled history of mRNA vaccines. Nature. 2021; 597(7876):318-324. DOI: 10.1038/d41586-021-02483-w. View

20.

Qiu M, Tang Y, Chen J, Muriph R, Ye Z, Huang C . Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2022; 119(8). PMC: 8872770. DOI: 10.1073/pnas.2116271119. View